Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Pten signaling in gliomas.

Knobbe CB, Merlo A, Reifenberger G.

Neuro Oncol. 2002 Jul;4(3):196-211. Review.

2.

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.

Steelman LS, Bertrand FE, McCubrey JA.

Expert Opin Ther Targets. 2004 Dec;8(6):537-50. Review.

PMID:
15584861
3.

PTEN: life as a tumor suppressor.

Simpson L, Parsons R.

Exp Cell Res. 2001 Mar 10;264(1):29-41. Review.

PMID:
11237521
4.

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.

Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo V, Ruvolo P, Kempf CR, Steelman LS, McCubrey JA.

Leukemia. 2011 Jul;25(7):1064-79. doi: 10.1038/leu.2011.46. Epub 2011 Mar 25. Review.

PMID:
21436840
5.

[PTEN expression in endometrial cancer and the prognosis].

Kanamori Y, Uegaki K, Kigawa J, Terakawa N.

Nihon Rinsho. 2004 Oct;62 Suppl 10:406-9. Review. Japanese. No abstract available.

PMID:
15535277
6.

PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling.

Paez J, Sellers WR.

Cancer Treat Res. 2003;115:145-67. Review. No abstract available.

PMID:
12613196
7.

Biological role of phosphatase PTEN in cancer and tissue injury healing.

Tsugawa K, Jones MK, Sugimachi K, Sarfeh IJ, Tarnawski AS.

Front Biosci. 2002 May 1;7:e245-51. Review.

PMID:
11991859
8.

The biology and clinical relevance of the PTEN tumor suppressor pathway.

Sansal I, Sellers WR.

J Clin Oncol. 2004 Jul 15;22(14):2954-63. Review.

PMID:
15254063
9.

PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis.

Besson A, Robbins SM, Yong VW.

Eur J Biochem. 1999 Aug;263(3):605-11. Review.

10.

PTEN and myotubularin: novel phosphoinositide phosphatases.

Maehama T, Taylor GS, Dixon JE.

Annu Rev Biochem. 2001;70:247-79. Review.

PMID:
11395408
11.

Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.

Downes CP, Bennett D, McConnachie G, Leslie NR, Pass I, MacPhee C, Patel L, Gray A.

Biochem Soc Trans. 2001 Nov;29(Pt 6):846-51. Review.

PMID:
11709086
12.

PI3K/Akt and apoptosis: size matters.

Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C.

Oncogene. 2003 Dec 8;22(56):8983-98. Review.

PMID:
14663477
13.

[PTEN tumor suppressor: functions as a lipid phosphatase].

Maehama T, Dixon JE.

Tanpakushitsu Kakusan Koso. 2000 Oct;45(14):2405-14. Review. Japanese. No abstract available.

PMID:
11051842
14.

[Genetic abnormalities in endometrial cancer].

Takeshima N, Hirai Y.

Nihon Rinsho. 2004 Oct;62 Suppl 10:254-8. Review. Japanese. No abstract available.

PMID:
15535246
15.

The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling.

Vazquez F, Sellers WR.

Biochim Biophys Acta. 2000 Feb 14;1470(1):M21-35. Review. No abstract available.

PMID:
10656987
16.

The tumour suppressor PTEN: involvement of a tumour suppressor candidate protein in PTEN turnover.

Maehama T, Okahara F, Kanaho Y.

Biochem Soc Trans. 2004 Apr;32(Pt 2):343-7. Review.

PMID:
15046605
17.

PTEN signaling pathways in glioblastoma.

Koul D.

Cancer Biol Ther. 2008 Sep;7(9):1321-5. Epub 2008 Sep 8. Review.

PMID:
18836294
18.

Introduction: multifaceted roles of lipids and their catabolites in immune cell signaling.

Ott VL, Cambier JC.

Semin Immunol. 2002 Feb;14(1):1-6. Review. No abstract available.

PMID:
11884225
19.

Biological mechanisms of glioma invasion and potential therapeutic targets.

Tysnes BB, Mahesparan R.

J Neurooncol. 2001 Jun;53(2):129-47. Review.

PMID:
11716066

Supplemental Content

Support Center